Leonard Calabrese, DO
Board Certified Rheumatologist and the Head, Section of Clinical Immunology Department of Rheumatic & Immunologic Disease
Cleveland, OH, United States
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Chemocentryx: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Jansen: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); UCB: Consultant (Ongoing)
COVID has presented a unique set of challenges for patients with rheumatologic conditions. In addition to concerns for immunosuppression and risk of infection, they have also faced drug shortages associated with use of their medications for treatment of COVID. In this session, presenters will discuss the convergence of rheumatology and infectious diseases in the management of COVID infections.
Speaker: Rachael Perritt, PharmD – Hospital of the University of Pennsylvania
Speaker: Stephen Saw, PharmD – Hospital of the University of Pennsylvania